Review of weight-loss injections for potential suicidal adverse effect

The European Medicines Agency (EMA) has announced that it is investigating some weight-loss injections in light of research showing that the injections were linked to suicidal thoughts and self-harm among users.

Following information from Iceland, a member state, that the pharmaceutical authority will first assess the risks connected with the treatment, which includes semaglutide or liraglutide, the EMA will look into Wegovy, Saxenda, and other drugs that assist people lower their hunger. 3 instancesThe British broadcaster stated that the EMA's Pharmacovigilance Risk Assessment Committee (PRAC), which is conducting the study, will investigate if other medications in the same larger class of drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, also need to be assessed.

Despite the fact that "these prescription drugs" are not mentioned for suicidal behaviours.

Comments

Popular posts from this blog

EXAMINATION TECHNIQUE (Specially Accounting)

"Standard Chartered Predicts Bitcoin's Value to Exceed $100,000"

Nice Information about the Languages you want